---
title: "Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | OGEN Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280534961.md"
description: "Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | OGEN Stock News"
datetime: "2026-03-25T14:30:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280534961.md)
  - [en](https://longbridge.com/en/news/280534961.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280534961.md)
---

# Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | OGEN Stock News

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation | OGEN Stock News

### Related Stocks

- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [OGEN.US](https://longbridge.com/en/quote/OGEN.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Oragenics advances ONP-002 Phase IIa in Australia, $6.1M cash and LOI for CNS device](https://longbridge.com/en/news/286915159.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)